替吉奥胶囊姑息治疗晚期恶性肿瘤的临床研究  

Clinical Study of TS-1 in Palliative Treatment of Advanced Cancer

作　　者：谢岳云[1] 余奕珲[1] 刘卫明[1] 冯亚琳[1] 田秀荣[1] 

机构地区：[1]中国人民解放军第一八一医院肿瘤科,541002

出　　处：《中国老年保健医学》2013年第3期53-55,共3页Chinese Journal of Geriatric Care

摘　　要：目的探讨替吉奥胶囊姑息治疗晚期恶性肿瘤的疗效及不良反应。方法收集2009年10月至2011年5月晚期恶性肿瘤51例,均采用单药替吉奥(TS-1),40mg/(m2·d),2次/日,连续口服四周,休息2周为一周期,每例患者至少接受治疗2个周期,治疗结束后进行评价有效率、生存率及不良反应。结果 51例患者均顺利完成化疗。总有效率(CR+PR)为29.4%。生活质量改善增加率(KPS大于80分)31.4%。随访6到12个月,采用Kaplan-Meier分析显示1年累积生存率为37.3%,无严重不良反应。结论替吉奥是姑息治疗晚期恶性肿瘤是一种安全而有效的方法。To investigate the clinical values and adverse reactions of TS-1 in palliative treatment of advanced cancer. Methods From October 2009 to May 2011,51 cases of advanced cancer treated by twice daily of TS-1 40mg / （m^2·d） ,bid,from day 1 to day 28,rest for 2 week,and repeated every six weeks. Each patient received at least two cycles. The effect,survival and adverse reactions were evaluated. Results 51 patients were successfully completed chemotherapy. The total effective rate （ CR ＋ PR） was 29. 4% . The improvement rate of the quality of life （ KPS more than 80 points） was 31. 4% . Follow-up for 6 to 12 months,the Ka-plan-Meier analysis showed that 1-year cumulative survival rate was 37. 3% ,with no serious adverse reactions. Conclusion TS-1 is a safe and effective method in palliative treatment of advanced cancer.

关 键 词：替吉奥胶囊 晚期恶性肿瘤 姑息化学治疗 

分 类 号：R730.5[医药卫生—肿瘤]